Najat Daw

17PUBLICATIONS
193CO-AUTHORS
Molecular targetsInfant and child healthCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|Apr 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

|Jan 01, 2026
Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaboration.

Michael V Ortiz, Francis S P L Wens, Andrew L Hong

|Nov 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.

Melinda Soeung, Xinmiao Yan, Ciro Zanca

|Jul 12, 2025
Ifosfamide-Induced Encephalopathy in Children and Young Adults: The MD Anderson Cancer Center Experience.

Shaikha Alqahtani, Sabrina D Bitar, Maria Estela Mireles

|Jul 02, 2024
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.

Paul A Meyers, Noah Federman, Najat Daw

Pageof 3

Frequent Collaborators

5 joint publications

John A Livingston

4 joint publications

Salah-Eddine Lamhamedi-Cherradi

4 joint publications

P Andrew Futreal

4 joint publications

Joseph Ludwig